High Dose Chemotherapy With Amifostine and Autologous Stem Cell Transplantation for High Risk Relapsed Pediatric Solid Tumors and Brain Tumors

• Status: Terminated
• Trial end date: 2012-04-24
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of amifostine to determine how effective it is in the reduction of infection in a high dose chemotherapy regimen with autologous stem cell rescue in children with high risk, relapsed or refractory pediatric solid tumors.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Hospital Medical Center, Cincinnati
• Treatments: Amifostine

Criteria

Inclusion Criteria:

• High risk Ewing's Sarcoma Family Tumors (ESFT) including Ewing's Sarcoma, Askin's tumor, peripheral PNET

• High risk desmoplastic small round cell tumors (DSRCT)

• Relapsed Wilm's tumor, diffuse anaplastic Wilm's tumor

• High risk brain tumors including PNET/Medulloblastomas/germinomas

• Relapsed germ cell tumors

• Metastatic or relapsed rhabdoid tumors

• Other relapsed/refractory pediatric embryonal tumors

• Less than 30 years of age

• Performance >= 50%

• Cancer Diagnosis verification and staging

• Disease Response and Recovery

• Adequate Organ Function (Renal, Liver, Cardiac)

Exclusion Criteria:

• Uncontrolled Infection

• Pregnancy or Breastfeeding (For Females)

• Disease Progression

• Uncontrolled Intercurrent Illness

• HIV Positive

• Receiving other Investigational Agents

• Amifostine Allergy